Hims & Hers Health (HIMS, Financial) saw its stock price rise over 5%, reaching a new record high of $32.23. The surge follows a report by Hunterbrook Media, which highlighted the potential benefits for Hims & Hers from the nomination of Marty Makary as the U.S. Food and Drug Administration (FDA) Commissioner. Makary is an executive at Sesame Inc., a startup that, like Hims & Hers, sells compounded GLP-1 weight loss medications.
Hunterbrook Media, known for its critical stance on short sellers like Citron Research, suggested that Makary's nomination could favor Hims & Hers due to his connections with Sesame Inc. The report also noted a shift in perspective from Hunterbrook Capital, a hedge fund under Hunterbrook Media. The fund has become optimistic about Hims & Hers' stock, contrasting with its previous short position in June, when concerns were raised about the company's online sales of GLP-1 injectables.
